Drugs / Vemircopan
Vemircopan
Trials 16 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 113 trials | ||||||
| Phase 1 | NCT06071442 | Jan → Apr 2024 | — | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05780645 | Mar 2023 → Feb 2024 | — | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05259085 | Apr 2022 → Aug 2024 | — | Alexion Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT05202145 | Jan → Mar 2022 | — | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04952545 | Jul → Sep 2021 | — | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04623710 | Jul 2021 → Feb 2022 | impaired renal function disease | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04933682 | Jun → Aug 2021 | — | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04609670 | Apr → Aug 2021 | — | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04660890 | Dec 2020 → Mar 2021 | — | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04551586 | Jun → Oct 2020 | — | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04709081 | Dec 2019 → Apr 2020 | — | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05047484 | Jan → Jul 2019 | — | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05047458 | Nov 2017 → Apr 2018 | — | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT05218096 | Apr 2022 → Nov 2023 | generalized myasthenia gravis | Alexion Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT05097989 | Jan 2022 → Dec 2024 | IgA glomerulonephritis, lupus nephritis | Alexion Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT04170023 | Dec 2019 → Apr 2023 | paroxysmal nocturnal hemoglobinuria | Alexion Pharmaceuticals, Inc. | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vemircopan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06071442 ↗ |
| Known as | ACH-0145228 | “A Phase 2 Open-Label Proof of Concept Study to Assess the Efficacy, Safety, and Pharmacokinetics of the Oral Factor D (FD) Inhibitor ALXN2050 (ACH-0145228) in Paroxysmal...” NCT04170023 ↗ |
| Known as | ACH-5228 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650325 ↗ |
| Known as | ALXN2050 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05202145 ↗ |
| Action | Inhibit | “Oral FD inhibitor” NCT04170023 ↗ |
| Modality | Small molecule | — CHEMBL4650325 ↗ |
| Route | Oral | “ALXN2050 orally administered” NCT04170023 ↗ |